Antwerp-based HealthTech startup Koios Care has closed a €1 million funding round to accelerate its efforts in transforming the monitoring and treatment of Parkinson’s Disease with its AI-powered platform that passively collects data from smartphones and smartwatches.
The round was led by Greek early-stage DeepTech investor Evercurious VC, with participation from Astylab Ventures, the imec.istart fund, and several angel investors, including those coordinated by HeBAN. The new funding will help Koios Care expand its digital health tool ‘Parkiwatch’ across European clinics, support regulatory clearance efforts, and build stronger partnerships with pharma companies and research institutions.
“There’s a significant gap between what people with Parkinson’s truly need and what they currently receive. It’s not just about managing symptoms, it’s about meaningfully improving their overall Quality of Life. That’s the gap Koios Care is here to close,” said Dr Konstantinos Kyritsis, Co-founder and CEO “One patient using the technology to clearly communicate with their neurologist told us, ‘Sometimes, on my current medication scheme, it feels like I have no Parkinson’s.’ That’s not just encouraging, it’s a powerful glimpse of what’s possible. It’s the kind of transformation we are relentlessly working to deliver for everyone living with this disease.”
Founded by Dr Konstantinos Kyritsis and Dr Dimitris Iakovakis, Koios Care bridges the gap between patients’ daily lives and clinical care. The team’s solution enables care teams to make earlier and more personalised decisions, based on objective, real-life evidence – rather than occasional clinic visits or self-reports.
Koios is developing an AI-powered platform that passively collects data from smartphones and smartwatches to provide clinicians and researchers with real-world, clinically meaningful insights into neurological disorders.
Koios Care is responding to it referrs to as a “silent pandemic” – the rapid global rise of Parkinson’s Disease, which reportedly now affects more than ten million people. By leveraging data from everyday devices, the company aims to personalise and improve care while streamlining clinical workflows and supporting more effective drug development.
Koios Care’s model supports both patients and the wider healthcare ecosystem. For clinicians and patients, it provides a digital tool to guide treatment decisions and monitor outcomes; for pharma and MedTech firms, it offers an R&D platform that can generate real-world data and identify meaningful endpoints for clinical trials.
“For too long, patients, clinicians and researchers have lacked continuous, objective data to truly personalise Parkinson’s care and understand the real-life impact of the disease and its treatments,” said Dr Iakovakis, Co-founder and CTO of Koios Care. “This funding reflects the urgent need for a new standard in care. With our solution, we empower patients to better understand their condition, equip medical teams with unprecedented insights, and provide pharmaceutical companies with a powerful tool to accelerate the development of more effective therapies.”
So far, Koios Care has studied 130 patients in a multi-centre EU trial and is working with hospital pilot sites and industry partners across Europe. The platform aligns with current regulatory guidance on digital health tools and is designed to improve therapeutic decision-making and trial success rates by reflecting real-world patient outcomes.
Alex Vamvakas, partner at Evercurious VC, commented, “Koios Care’s innovative approach to passively monitoring Quality of Life with everyday devices is a game-changer for neurodegenerative disorders. We are impressed by the team’s scientific rigor, the clinical validation and the vision to reshape long-term neurodegenerative conditions’ care and enable the shift toward personalised, data-driven disease management at scale.
“With roots in Greece and Belgium, and collaborators across Europe, Koios Care exemplifies the kind of region bridging, discipline spanning, impact-driven innovation that a more connected European DeepTech ecosystem can unlock. It reflects a vision of Europe where scientific excellence and entrepreneurial ambition transcend borders to solve pressing global challenges.”
Looking forward, Koios Care plans to develop drug-device combination products and expand its reach to other brain and behaviour-related conditions, including Mild Cognitive Impairment, Alzheimer’s, narcolepsy, and eating disorders. The startup is targeting areas where real-time, real-world data remains a critical missing link in care and research.
